PARTNERING

At ReForm, we are not only developing our own pipeline of biobetter biologics formulations, we are working with biopharmaceutical partners to advance and improve the characteristics of their biologics.

Formulating highly concentrated biopharmaceuticals present challenges due to viscosity. Most biologics are dosed intravenously and require multiple dosing regimens because these viscous materials need to be diluted and administered via prolonged infusions. In many cases, subcutaneous injection would be preferred, but viscosity interferes with injecting large doses through fine-gauge needles.

ReForm Biologics works with our partners to address these challenges. ReForm offers a portfolio of science-based platforms to assist our partners in meeting their product development goals and their patients’ needs for more easily administered and better tolerated biologic therapeutics.

We extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. We offer formulation development collaboration and product-specific licenses for a broad spectrum of protein-based therapeutics.

Technologies Include:

Viscosity
Reducing excipients for high concentration biologic formulations, to enable subcutaneous injection or device-assisted administration, or to improve filtration unit operations.
Stability
Enhancing excipients, to prevent aggregation and particle formation in biologics.
Surfactant
Replacing excipients, to avoid the degradation problems that accompany known surfactants for biological formulations.
Viscosity
Reducing excipients for high concentration biologic formulations, to enable subcutaneous injection or device-assisted administration, or to improve filtration unit operations.
Stability
Enhancing excipients, to prevent aggregation and particle formation in biologics.
Surfactant
Replacing excipients, to avoid the degradation problems that accompany known surfactants for biological formulations.
New formulations, such as those that ReForm offers, can be leveraged by biopharmaceutical companies to retain market share and maximize value creation via product line extension. ReForm’s excipients allow formulators to add value and to differentiate their products. Our excipients can also be employed in protein manufacturing, purification, and processing to improve filtration and production efficiency.

ReForm structures its partnerships in an open and science-driven manner, to collaborate with pharmaceutical companies as they develop innovative biologic treatments.

 

For more information, contact:

Jeff Hackman, CEO, Reform

12 Gill Street, Suite 4650
Woburn, MA 01801, USA
Phone: 617-871-2101
Email: info@reformbiologics.com